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Abstract
Background: High sensitive troponin T (hsTnT) and heart fatty acid binding protein (hFABP) are both markers of
myocardial injury and predict adverse outcome in patients with systolic heart failure (SHF). We tested whether
hsTnT and hFABP plasma levels are elevated in patients with heart failure with normal ejection fraction (HFnEF).
Methods: We analyzed hsTnT, hFABP and N-terminal brain natriuretic peptide in 130 patients comprising 49 HFnEF
patients, 51 patients with asymptomatic left ventricular diastolic dysfunction (LVDD), and 30 controls with normal
diastolic function. Patients were classified to have HFnEF when the diagnostic criteria as recommended by the
European Society of Cardiology were met.
Results: Levels of hs TnT and hFABP were significantly higher in patients with asymptomatic LVDD and HFnEF
(both p < 0.001) compared to controls. The hsTnT levels were 5.6 [0.0-9.8] pg/ml in LVDD vs. 8.5 [3.9-17.5] pg/ml in
HFnEF vs. <0.03 [< 0.03-6.4] pg/ml in controls; hFABP levels were 3029 [2533-3761] pg/ml in LVDD vs. 3669 [2918-
4839] pg/ml in HFnEF vs. 2361 [1860-3081] pg/ml in controls. Furthermore, hsTnT and hFABP levels were higher in
subjects with HFnEF compared to LVDD (p = 0.015 and p = 0.022).
Conclusion: In HFnEF patients, hsTnT and hFABP are elevated independent of coronary artery disease, suggesting
that ongoing myocardial damage plays a critical role in the pathophysiology. A combination of biomarkers and
echocardiographic parameters might improve diagnostic accuracy and risk stratification of patients with HFnEF.
Background
Nearly half of the patients with symptoms and signs of
heart failure have a normal ejection fraction(EF) [1,2], a
condition termed “heart failure with normal ejection
fraction” (HFnEF). The overall mortality in patients with
HFnNF is similar to that in patients with systolic heart
failure (SHF) [1,3]. Furthermore, asymptomatic left ven-
tricular diastolic dysfunction (LVDD), which is consid-
ered as a precursor of HFnEF, is a powerful and
independent predictor of death [4]. Nevertheless, rando-
mized trials in patients with HFnEF have failed to
demonstrate a reduction in mortality [5]. This is pre-
sumably related to the considerable heterogeneity
among patients with HFnEF and the lower proportion
of specific heart failure related death in this population
[6]. It is likely that the non-cardiovascular mortality in
HFnEF patients contributes disproportionately to their
all-cause mortality. Therefore, better characterization
and accurate diagnosis of patients with HFnEF at great-
est risk for heart failure related death would allow a
more effective use of a specific therapy. In this regard,
the diagnostic accuracy of echocardiography has been
limited.
Circulating biomarkers have become increasingly
important in diagnosing and risk stratifying patients
with chronic heart failure (HF) [7,8].
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become an established diagnostic marker of heart failure
and has been integrated in the guidelines [8,9], including
diagnosis of HFnEF [10]. Recently, a highly sensitive
commercial assay of cardiac troponin T (hsTnT) became
available [11,12]. Using this assay, increased hsTnT
levels were detected in the majority of patients with
chronic systolic heart failure (SHF) [13] or ischemic
heart disease, providing independent prognostic infor-
mation with respect to heart failure admission and car-
diovascular death [14,15].
Likewise, heart fatty acid binding protein (hFABP) has
been reported to be associated with an increased risk of
death in patients with SHF [16-18]. However, the use as
a screening tool in subjects with LVDD or HFnEF
remains to be established. This study sought to evaluate
whether hsTnT and hFABP are elevated in patients with
LVDD or HFnEF independent of coronary anatomy.
Methods
Study population
One hundred thirty consecutive hospitalized subjects
referred to elective coronary angiography for the diag-
nostic workup of exercise intolerance, stable or sus-
pected coronary heart disease (CAD) were enrolled in
this study. Patients with the need for coronary revascu-
larization either with angioplasty or coronary bypass
surgery were excluded from further analysis. The proto-
col was approved by the local ethics committee, and
signed informed consent was obtained from all patients.
Inclusion criteria were scheduled coronary angiography,
age 18-80 years and normal left ventricular ejection frac-
tion (EF) ≥ 50%. Exclusion criteria were hypertrophic or
infiltrative cardiomyopathy, moderate-to-severe valvular
disease, atrial fibrillation or other severe arrhythmias,
alcoholism, or serum-creatinine > 2.5 mg/dl. Consider-
ing the association between diabetes, HFnEF [19,20] and
hsTnT release [21], we performed a standardized oral
glucose tolerance test (oGTT, 75 g glucose) as pre-
viously described [22] in all patients without diabetes.
Echocardiography
Echocardiography was performed using a standard ultra-
sound system (Vivid 7, General Electrics, Milwaukee,
Wisconsin). Standard echocardiographic 2D measure-
ments were performed according to current guidelines
[23]. Conventional transmitral flow was measured with
pw-Doppler. Early (E), late atrial (A) transmitral peak
flow velocities and the ratio (E/A) were measured.
Pulsed wave tissue Doppler imaging (TDI) was per-
formed at the junction of the left ventricular (LV) wall
with the septal and lateral mitral annulus and three con-
secutive beats were averaged. Early diastolic velocities (E
″medial, E″ lateral) were recorded; the mean value (E″
average) from E″ at the medial and lateral mitral annu-
lus was determined. Ratios of E/E″ medial, E/E″ lateral
and average E/E″ ratio were calculated. Patients were
classified to have HFnEF when the diagnostic criteria as
recommended by the European Society of Cardiology
were met [10]. In summary, there criteria include an E/
E″ratio > 15 and NT-proBNP levels > 220 pg/ml. Mild
asymptomatic left ventricular diastolic dysfunction
(LVDD) was defined as E″ medial < 8 cm/s, the E/E″
medial ratio 8-15, NT-proBNP levels < 220 pg/ml and
an E/A ratio < 0.8 cm/s.
Biomarker
Before coronary angiography, blood samples were col-
lected. The plasma supernatant was separated and
stored frozen at -80°C until analysis. All laboratory mea-
surements on the new hsTnT, NT-proBNP and hFABP
were performed in the research laboratory of Roche
Diagnostics, Penzberg, Oberbayern.
Troponin T concentrations were measured with high
sensitive troponin T reagents on an Elecsys 2010 analy-
zer (Roche Diagnostics, Indianapolis, Indiana), with an
analytical measurement range of 3-10000 ng/L or pg/
mL. In studies performed with the Elecsys Troponin T
high sensitive assay involving 533 healthy volunteers, the
upper reference limit (99th percentile) for troponin T
was 14 ng/L (pg/mL), 95% confidence interval 12.7-24.9
ng/L (pg/mL).
Heart acid fatty binding protein levels were measured
on a human H-FABP ELISA kit (Hycult biotech) with an
analytical measurement range of 102 to 25.000 pg/ml.
Details of NT-proBNP measurements have been
described previously [24].
Statistical Analysis
All analyses were performed using SPSS statistical soft-
ware (SPSS 19.0, Chicago, IL). The data are presented as
median with 25
th/75
th percentiles (interquartile range)
for continuous variables or absolute number (%) for
categorical variables unless otherwise specified. Log
transformed values were used for analysis as appropri-
ate. A p value < 0.05 was considered statistically signifi-
cant. The Mann-Whitney U-test was used to analyze
differences between the medians of two groups and the
Kruskal Wallis test to test the equality of medians
among more than two distinct groups. Fisher″s Test was
used for the comparison of two sets of binary variables
and the c2 test to evaluate differences in proportions in
more than 2 sets of categorical variables.
High sensitive troponin T and hFABP were compared
across subjects with normal diastolic function, mild
LVDD and HFnEF by the Jonckheere-Terpstra test. We
used the Spearman rank correlation to identify variables
associated with biomarkers. Multiple linear regression
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pendently associated with hsTnT and hFABP levels.
Results
Patient characteristics
We included 130 patients with normal EF ≥ 50% (med-
ian age 67 [59-73] years, 49% woman) in the study, 62%
of whom had stable CAD (defined as coronary stenosis
>5 0 %i n≥ 1 coronary artery) without the need for cor-
onary revascularization. The study group was subdivided
as having either HFnEF (n = 49), asymptomatic left ven-
tricular diastolic dysfunction (LVDD, n = 51) and nor-
mal diastolic function (controls, n = 30). An oGTT was
performed in 95 individuals, of whom 38 (29%) had a
normal glucose tolerance (NGT), 34 (26%) had impaired
glucose tolerance and 23 (18%) had a new detected dia-
betes mellitus. Thirty-five patients had a history of type
2 diabetes mellitus before inclusion; therefore, 58 (45%)
individuals included in the study were identified with
type 2 diabetes mellitus (T2DM).
The clinical characteristics in patients classified as to
the presence or absence of LVDD or HFnEF are shown
in table 1, the laboratory data and parameter of cardiac
assessment are highlighted in table 2.
High sensitive troponin T, hFABP and diastolic function
High sensitive troponin T and hFABP levels increase
significantly from controls to asymptomatic LVDD and
HFnEF (both p < 0.001, figure 1 and 2).
Furthermore, hsTnT and hFABP levels were higher in
subjects with HFnEF compared to asymptomatic LVDD
(p = 0.015 and p = 0.022, respectively). In multivariate
analysis including age, sex, CAD, EF, body mass index
and diabetes, the presence of HFnEF remains the only
factor significantly associated with hsTnT levels (p =
0.009). Furthermore, hFABP was significantly higher in
the asymptomatic LVDD group compared to those with
normal diastolic function (3029 [2533-3761] pg/ml in
LVDD vs. 2361 [1860-3081] in controls; p = 0.007),
whereas hsTnT was not significantly different between
the LVDD and controls (p = 0.068).
Excluding subjects with CAD, we found that hsTnT was
detectable, at a level of 3.0 pg/ml or greater, in 87% of
HFnEF patients, in 65% of the LVDD group, and in 36% of
the control group subjects (p = 0.017). Furthermore,
hsTnT was detectable above the upper reference limit of
14.0 pg/ml in 33% of HFnEF patients, in 15% of the LVDD
group, and in 0% of the control group subjects (p = 0.05).
Overall, in subjects without CAD, hsTnT and hFABP
levels remain significantly associated with the presence
and severity of diastolic dysfunction (p < 0.001, table 3).
Overall, in subjects without CAD, hsTnT and hFABP
levels remain significantly associated with the presence
and severity of diastolic dysfunction (p < 0.001, table 3).
The relationship between hsTnT and hFABP quartiles,
cardiac assessment and NT-pro-BNP levels is shown in
table 4 and 5. Particularly among the association with
echocardiographic parameters of diastolic dysfunction,
hsTnT and hFABP levels were significantly increasing
across the E/E″ ratio, a parameter indicative for elevated
ventricular filling pressures. There was a weak linear
correlation between NT-proBNP levels with hsTnT (r =
0.331, p < 0.001) and hFABP levels (r = 0.330, p <
0.001).
In contrast to diastolic function parameter, left ventri-
cular ejection fraction and the global longitudinal strain
values, a very sensitive tool to detect systolic dysfunction
disregarding a normal EF, were not associated with
hsTnT or hFABP levels (both p > 0.05).
Discussion
We have demonstrated for the first time that hsTnT
and hFABP plasma levels are associated with the diag-
nosis of HFnEF. The association is in proportion to the
severity of the disease. Furthermore, hFABP was signifi-
cantly different in subjects with normal DF and asymp-
tomatic LVDD, whereas whereas hsTnT was not
significantly different between the LVDD and controls.
Both hsTnT and hFABP levels correlate significantly
with multiple echocardiographic criteria implemented in
guidelines for the diagnosis and classification of LVDD
and HFnEF.
High sensitive troponin T
The recent introduction of a new generation hsTnT has
not only improved the early diagnosis of acute coronary
syndromes, but also suggested that there are several
causes for troponin T release other than myocardial
ischemia. Particularly patients with SHF were found to
have detectable levels of hsTnT with a persistent rela-
tionship between magnitude and outcome. In several
cohorts of patients with SHF, the magnitude of troponin
elevation has been correlated with the severity of the
disease and with adverse outcomes [25,26]. The Val-
HeFT trial [13] showed an almost linear increase in the
risk of adverse clinical event with hsTnT concentration
in patients with SHF, even in a range of very low con-
centrations that could not be measured with the tradi-
tional assay. In this trial, measurement of hsTnT adds
to the prognostic information provided by natriuretic
peptides alone. Patients with both cardiac markers ele-
vated had a worse prognosis than those with a single
elevated marker.
Furthermore, in the general population, hsTnT was
associated with structural heart disease and subsequent
risk for all-cause mortality [27]. A recent study has
shown that low levels of hsTnT are associated with
new-onset heart failure and cardiovascular death in
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disease, independent of other risk factors [28], and a
large observation study in Europe has shown an associa-
tion between low levels of circulating troponin T and
the future development of HF in completely asympto-
matic subjects [29]. We were able to demonstrate a
strong association between hsTnT and the diagnosis of
HFnEF, independent of CAD. Therefore, analogous to
SHF, we hypothesize that hsTnT might improve diag-
nostic accuracy and risk stratification in HFnEF.
Heart fatty acid binding protein
Heart fatty acid binding protein is abundant in the cyto-
sol of cardiomyocytes and is released when cell surface
membrane is injured [30]. In advanced SHF, hFABP
levels are increased because of the leakage of cytosolic
proteins from cardiomycates affected by the ongoing
myocardial damage [17,24,31,32]. Circulating levels of
hFABP have a prognostic value regarding the future
deterioration of congestive heart failure in patients with
dilated cardiomyopathy [16,33], and persistently
increased serum concentrations of hFABP predict
adverse clinical outcomes in patients with SHF [16].
Our data show a significant association between hFABP
and the severity of diastolic dysfunction.
In contrast to hsTnT, hFABP was significantly
increased in the asymptomatic LVDD group compared
to controls. hFABP is a cytosolic protein, whereas tropo-
nin is a myofibrillar protein with a cytosolic pool esti-
mated at only 6% to 8% [34]. A reversible myocyte
injury resulting in increased membrane permeability
would cause an early hFABP release, while a more
extensive injury must occur before significant amounts
of troponin are released. LVDD, which is considered as
a precursor of HFnEF, carries a substantial risk for the
subsequent development of HFnEF and reduced survi-
val, even when it is asymptomatic [4]. Considering the
large number of patients at risk for or with
Table 1 Clinical characteristics
Normal DF (n = 30) mild LVDD (n = 51) HFnEF (n = 49) p-value All (n = 130)
Clinical variables
Age (years) 60 (50-66) 65 (57-69) 72 (67-76) <0.001* 67 (59-73)
Female gender 15 (50) 21 (41) 28 (57) 0.278 64 (49)
BMI (kg/m
2) 26 (24-32) 27 (25-31) 28 (25-31) 0.236 27 (25-32)
Systolic BP (mmHg) 123 (110-130) 130 (126-142) 138 (130-140) <0.001* 130(122-140)
Diastolic BP (mmHg) 76 (70-80) 80 (76-86) 80 (70-84) 0.023* 80(70-83)
CAD 16 (53) 31 (61) 34 (69) 0.346 81 (62)
Previous MI 7 (23) 7 (14) 14 (29) 0.189 28 (22)
Previous stroke 0 2 (4) 2 (4) 0.339 4 [39]
Previous PTCA 14 (46) 25 (496) 25 (51) 0.905 64 (49)
Cardiovascular risk factors
Treated hypertension 23 (77) 46 (90) 47 (96) 0.010* 116 (89)
Smoking 7 (23) 8 (16) 6(12) 0.041* 21 (16)
Family history CAD 15 (50) 29 (57) 20 (42) 0.669* 64 (50)
Hyperlipidaemia 14 (46) 38 (74) 33 (67) 0.037* 85 (65)
Glucose metabolism status
NGT 13 (43) 13 (25) 12 (24) 0.013* 38 (29)
IGT 11 (37) 13 (25) 10 (20) 34 (26)
New detected T2DM 3 (10) 8 (16) 12 (24) 23(18)
Known T2DM 3 (10) 17 (33) 15 (31) 35 (29)
Medications
ACE inhibitor 17 (56) 29 (57) 34 (69) 0.359 80 (61)
AT1 blocker 2 (7) 8 (16) 11 (22) 0.179 21 (16)
Diuretics 5 (17%) 12 (24) 24 (49) 0.003* 41 (32)
Ca
2+ blocker 4 (13) 6 (12) 17 (34) 0.011* 27 (21)
ß-Blocker 21 (70%) 32 (63) 42 (86) 0.032* 95 (73)
Insulin therapy 0 8 (20) 6 (15) 0.128 14 (11)
OAD 1 (6) 13 (34) 5 (12) 0.012* 19 (15)
Values are median (interquartile range) or n (%), * statistically significant (p < 0.05). BMI = Body mass index, BP = blood pressure, CAD = Coronary Artery Disease,
CABG = coronary bypass graft, DF = diastolic function, HFnEF = heart failure with normal ejection fraction, IGT = impaired glucose tolerance, LVDD = left
ventricular diastolic dysfunction, NGT = normal glucose tolerance, OAD = oral anti-diabetic therapy, PTCA = percutaneous coronary angioplasty, T2DM = type 2
diabetes mellitus
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provide an opportunity to manage the underlying cause
and prevent progression to symptomatic diastolic heart
failure. Accordingly, hsFABP may be a more sensitive
and reliable indicator of low-level myocardial damage in
LVDD, especially when used together with troponins
[16,17].
Pathophysiological considerations
Elevated hsTnT and hFABP levels in patients with
HFnEF may suggest ongoing myocardial damage at a
very low rate [31], indicating that these biomarkers
may serve as a marker for the progression of heart fail-
ure [35]. In our study, hsTnT and hFABP were
increased in patients with HFnEF independent of CAD.
Hence, this phenomenon seems to be independent of
an ischemic injury. Stretching of myocytes might lead
to leakage of troponins and hFABP by transient loss of
cell membrane integrity without cell death [36]. This
reversible damage may contribute to the increase in
circulating cardiac troponins caused by irreversible
damage of myocytes [26]. Nevertheless, persistently
elevated hsTnT and hFABP values in HFnEF patients
should lead to an evaluation for ischemic heart disease,
if not already performed.
According to the diagnostic criteria as recommended
by the European Society of Cardiology in 2007 [10], N-
terminal brain natriuretic peptide (NT-proBNP) is
regarded as the preferred biomarker for the detection of
HFnEF. Nevertheless, in our study, the correlation
between NTproBNP and hsTnT or hFABP was only
moderate, suggesting that BNP and specific myocardial
proteins convey different and complementary features of
the pathophysiologic process. The former is released in
response to the pressure overload and the latter reflects
structural alterations in the myocardium and ongoing
myocardial damage. In patients with SHF, it has been
reported that the combined measurement of BNP and
troponin can predict adverse cardiac events [37]. Conse-
quently, these biomarkers may provide different diag-
nostic or prognostic information in patients with
HFnEF.
Table 2 Laboratory data and echocardiographic parameter of cardiac assessment
Normal DF (n = 30) mild LVDD (n = 51) HFnEF (n = 49) p-value
Biomarker
NT-proBNP (pg/ml) 89 (43-120) 81 (54-118) 444 (251-937) <0.001*
hsTnT (pg/ml) < 3 (< 3-6.4) 5.6 (< 3-9.8) 8.5 (3.9-17.5) 0.001*
hFABP (pg/ml) 2361 (1860-3081) 3029 (2533-3761) 3669 (2918-4839) <0.001*
Routine parameter
LDL (mg/dl) 106 (92-130) 106 (84-134) 111 (84-137) 0.927
HDL (mg/dl) 53 (45-68) 53 (39-63) 49 (42-60) 0.823
Triglyceride (mg/dl) 125 (100-210) 146 (103-233) 152 (115-206) 0.762
Creatinin (mg/dl) 0,9 (0,7-1,0) 0,9 (0,8-1,0) 0,9 (0,8-1,2) 0.050
Hba1c (%) 5,7 (5,5-6,1) 6,1 (5,8-7,0) 6,2 (5,7-6,6) 0.004*
Systolic function
Ejection fraction (%) 63(60-67) 67 (61-71) 67 (63-73) 0.103
GLS ( -,%) 19,0 (19,9-17,3) 20,3 (21,8-16,9) 18,6 (21,2-16,5) 0.323
LV geometry
LVEDD (mm) 43 (41-48) 43 (39-47) 45 (40-48) 0.413
LVMi (g/m
2) 75 (64-97) 84 (68-104) 100 (76-135) 0.011*
Diastolic function
LA- Index (ml/m
2) 27,5 (23,9-29,2) 28,1 (23,7-31,1) 39,1 (34,2-49,1) <0.001*
E (cm/s) 60 (50-60) 60 (60-70) 70 (60-90) <0.001*
A (cm/s) 70 (50-70) 80 (70-90) 80 (70-90) <0.001*
E/A ratio 0,86 (0,71-1,18) 0,78 (0,71-0,89) 0,88 (0,77-1,25) 0.055
E’ septal (cm/s) 8,0 (7,1-8,9) 5,9 (5,1-7,1) 5,6 (4,8-6,2) <0.001*
E’ lateral (cm/s) 10,4 (8,8-11,6) 8,2 (6,7-9,2) 7,3 (5,8-9,0) <0.001*
E/E’ septal ratio 7,1(6,2-7,7) 10,6 (8,8-12,2) 12,8 (10,9-16,4) 0.001*
E/E’ average ratio 6,50(5,6-6,9) 9,0 (7,8-10,5) 11,2 (9,5-14,5) <0.001*
Values are median (interquartile range). * Statistically significant (p < 0.05). A = late diastolic transmitral inflow velocity, EF = ejection fraction. DF = diastolic
function, GLS = global longitudinal strain, LA = left atrial, E = early diastolic transmitral inflow velocity, E″ septal = early diastolic tissue doppler velocity septal, E″
lateral = early diastolic tissue doppler velocity lateral, HFnEF = heart failure with normal ejection fraction, hFABP = heart fatty acid binding protein, hsTnT = high
sensitive troponin T, LVEDD = left ventricular end-diastolic diameter, LV = left ventricular, LVMi = left ventricular muscle mass index, NT-proBNP = amino-terminal
pro-B-type natriuretic peptide.
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Page 5 of 9Figure 1 High sensitive troponin T (hsTnT) levels plotted against diastolic function in patients with normal diastolic function
(controls), mild asymptomatic left ventricular diastolic dysfunction (LVDD) and heart failure with normal ejection fraction (HFnEF).
hsTnT levels are log transformed and presented as box (25th percentile, median, 75th percentile) and whiskers plots. Upper outliers are
presented as black dots (>1.5 times box high).
Figure 2 Heart fatty acid binding protein (hFABP) levels plotted against diastolic function in patients with normal diastolic function
(controls), mild asymptomatic left ventricular diastolic dysfunction (LVDD) and heart failure with normal ejection fraction (HFnEF).
hFABP levels are log transformed and presented as box (25th percentile, median, 75th percentile) and whiskers plots. Upper and lower outliers
are presented as black dots (>1.5 times box high); asterisks indicates extreme cases (>3 times of box high).
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In daily clinical practice, although specific recommen-
dations have been proposed [10,38], affirmation of
HFnEF is challenging because the HFnEF population is
heterogeneous, and HFnEF is probably not necessarily
a single entity. This implies a high risk for either a
false positive or false negative diagnosis by the defining
diagnostic criteria. Consequently, identification of
potentially pathophysiologically distinct subgroups of
HFnEF patients could advance diagnosis and therapy.
Particularly, a test that identifies which patients with
HFnEF are at increased risk for cardiovascular events
would be desirable. In this regard, changes in different
biomarker levels in HFnEF are of scientific interest, as
they reflect distinct disease mechanisms in heart
failure.
Limitations
Interpreting the present data is limited by the small
number of the patients studied, resulting in a limited
statistical power. Furthermore, the rates of CAD and
cardiovascular risk factors were high in this study popu-
lation. Therefore, the present results may not be readily
representing the general population. Nevertheless, the
association between diastolic function, hsTnT and
hFABP remains significant after adjustment for CAD,
glucose metabolism and hypertension as covariates into
multivariate regression models. Furthermore, for risk
stratification, follow-up and association of the biomar-
kers with clinical events is needed. Lastly, we did not
perform serial measurements and only focused on base-
line values. Accordingly, our cross sectional study design
does not permit any conclusions on causality.
Table 3 Laboratory data in subjects with or without stable coronary artery disease
Normal DF mild LVDD HFnEF p-value
No CAD n = 14 n = 20 n = 15
NT-proBNP (pg/ml) 66 (38-91) 90 (56-116) 381 (236-1147) <0.001*
hsTnT (pg/ml) < 3 (< 3-5.6) 4.5 (< 3-8.9) 8.5 (5.4-18.7) 0.001*
hFABP (pg/ml) 2066 (1822-2432) 3138 (2637-3818) 3710 (3126-8354) <0.001*
CAD n = 16 n = 31 n = 34
NT-proBNP (pg/ml) 95 (55-137) 78 (54-122) 481 (253-4685) <0.001*
hsTnT (pg/ml) < 2.85 (< 3-8.7) 6.9 (< 3-10.0) 9.2 (3.6-17.5) 0.023*
hFABP (pg/ml) 3017 (2210-3661) 2956 (2533-3340) 3390 (2825-4685) 0.048*
Values are median (interquartile range. CAD = coronary artery disease, hFABP = heart fatty acid binding protein; HFnEF = heart failure with normal ejection
fraction; hsTnT = high sensitive troponin T, LVEDD = left ventricular end-diastolic diameter; NT-proBNP = amino-terminal pro-B-type natriuretic peptide. *
Statistically significant (p < 0.05).
Table 4 Parameter of cardiac assessment according to hsTnT quartiles
1rd Quartile 2nd Quartile 3rd Quartile 4th Quartile p- value
hsTnT (pg/ml) Systolic function <3 (n = 44) <3-5.6 (n = 18) 5.7-11.3(n = 37) 11.3-92.1 (n = 31)
Ejection fraction (%) 66 (62-72) 62 (57-69) 66 (63-70) 65 (61-74) 0.267
GLS ( -,%) 19,8 (21,6-18,0) 19,2 (21,0-16,8) 18,9 (21,4-16,6) 18,3 (21,1-16,0) 0.477
LV Geometry
LVEDD (mm) 44 (41-48) 43 (42-50) 45 (39-48) 43 (40-47) 0.804
LVMi (g/m
2) 81 (68-89) 94 (74-121) 90 (70-107) 107 (69-138) 0.013*
Diastolic function
LA- Index (ml/m
2) 28 (23-34) 30 (24-33) 30 (27-37) 35 (29-39) 0.012*
E/A ratio 0,86 (0,75-1,20) 0,75 (0,68-0,85) 0,80 (0,71-1,00) 0,87 (0,75-1,00) 0.128
E’ septal (cm/s) 7,3 (5,3-8,0) 6,2 (4,7-7,3) 5,9 (5,3-7,1) 5,7 (4,5-6,2) 0.004*
E’ lateral (cm/s) 9,0 (7,2-10,43) 9,2 (6,1-10,8) 8,1 (6,7-9,1) 7,2 (5,6-8,2) 0.025*
E/E’ septal ratio 9,0 (7,5-12,1) 10,4 (9,18-11,6) 11,2 (8,3-13,1) 11,8 (8,9-15,7) 0.023*
E/E’ average ratio 7,83 (6,60-9,76) 8,89 (7,16-10,59) 9,45 (7,72-12,05) 10,4 (8,15-13,37) 0.015*
Laboratory
NT-proBNP (pg/ml) 104 (49-166) 102 (52-223) 150 (93-265) 261 (78-926) 0.005*
Values are median (interquartile range). * Statistically significant (p < 0.05). A = late diastolic transmitral inflow velocity, EF = ejection fraction. GLS = global
longitudinal strain, LA = left atrial, E = early diastolic transmitral inflow velocity, E″septal = early diastolic tissue doppler velocity septal, E″lateral = early diastolic
tissue doppler velocity lateral, hsTnT = high sensitive troponin T, LV = left ventricular, LVEDD = left ventricular enddiastolic diameter, LVMi = left ventricular
muscle mass index, NT-proBNP = amino-terminal pro-B-type natriuretic peptide.
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Page 7 of 9Conclusions
This is the first study to show that circulating hsTnT
and hFABP are elevated in patients with HFnEF inde-
pendently of CAD. Nevertheless, the mechanisms of car-
diac injury in HFnEF resulting in hsTnT and hFABP
release need to be further elucidated.
Incorporation of a multimarker strategy, reflecting dis-
tinct pathophysiological mechanisms, may improve diag-
nostic accuracy and risk prediction in HFnEF beyond
traditional risk indicators. Further studies assessing mor-
tality and morbidity are needed to evaluate whether the
use of hsTnT and hFABP can guide the identification of
HFnEF at high risk.
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